EPHX2 emerges as an Alzheimer’s target in genetic and mouse tests
A single peer-reviewed study identifies EPHX2 as a candidate Alzheimer’s drug target by combining human genetic evidence with laboratory experiments. An inhibitor reduced amyloid burden and inflammation in mice, alongside improvements in behavioural tasks. Patient-derived cells and observational health data provided further tests, but the findings have not established a treatment benefit in people.
Science··Night
Mouse tests follow a genetically selected target
EPHX2, the gene encoding the soluble epoxide hydrolase enzyme, emerged as an Alzheimer’s drug target in one peer-reviewed investigation. An inhibitor called EC5026 reduced amyloid burden and microglia-associated inflammation in 5xFAD mice, an experimental model of Alzheimer’s disease. Treated animals also improved on three kinds of task: water-maze, object-recognition and fear-conditioning tests. The starting design used 12 mice in each group, divided equally between females and males.[1]
Human genetics guides the laboratory work
Researchers first evaluated seven genome-wide association datasets involving European and African ancestry. Usable genetic instruments were available for 1,229 drug-related genes or proteins. The target list numbered 19 for the European-ancestry analyses, compared with seven for the African-ancestry analyses. Alzheimer’s risk was higher where the genetic analysis indicated elevated EPHX2 protein, The p.Arg287Gln variant, by contrast, was associated with reductions in both protein levels and risk.[1]
Patient-derived stem-cell neurons and cerebral organoids associated the variant with reduced phosphorylated tau. Editing the gene supplied another confirmation that EPHX2 protein was reduced. These experiments supplemented the genetic selection with tests in cells and laboratory models.[1]
Prescribing data remain observational
A separate analysis assessed 210 commonly prescribed drugs among 111,680 people using their health data. All had mild cognitive impairment. In all four exposure models, twelve drugs had an association with reduced Alzheimer’s incidence. Prescriptions were not randomly assigned, and diagnoses were rarely confirmed with imaging or cerebrospinal-fluid biomarkers. The findings identify candidates for further research alongside the cell and animal experiments. Treatment benefit in people remains unestablished.[1]
